Advances in application of adipose-derived mesenchymal stem cells in autoimmune diseases

doi:10.3969/j.issn.1674-8115.2022.08.019

Abstract

Abstract:

The occurrence and development of autoimmune diseases is due to the decrease or even destruction of the patient's autoimmune tolerance, and excessive production of autoantibodies and/or sensitized lymphocytes in the body, resulting in histopathological changes and clinical phenotypes. At present, the main clinical treatment is the drug-based non-specific immunosuppression therapy. Although it can relieve some patients' symptoms, for severe patients, the effect is often not ideal. In recent years, with the in-depth study of mesenchymal stem cells (MSCs), people's understanding of their characteristics has gradually expanded from highly self-renewal and differentiation ability to immunomodulatory function. At the same time, the research direction based on MSCs has gradually shifted from regenerative medicine to the field of autoimmunology. With the development of preclinical and clinical trials, systemic or local application of adipose-derived mesenchymal stem cells (AD-MSCs) has been gradually recognized as one of the effective methods for clinical treatment of autoimmune diseases. In this review, the biological characteristics of AD-MSCs and their application to autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, systemic scleroderma, and psoriasis, are highlighted.

Key words: adipose-derived mesenchymal stem cells (AD-MSCs), immune regulation, autoimmune diseases, clinical application

CLC Number:

R459.9

LI Yuehua, LI Qingfeng, XIE Yun. Advances in application of adipose-derived mesenchymal stem cells in autoimmune diseases[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(8): 1131-1138.

Figures/Tables 1

TrendMD

References 58

1	HELLESEN A, BRATLAND E, HUSEBYE E S. Autoimmune Addison's disease: an update on pathogenesis[J]. Ann D'endocrinologie, 2018, 79(3): 157-163.
2	ROSE N R. Prediction and prevention of autoimmune disease in the 21st century: a review and preview[J]. Am J Epidemiol, 2016, 183(5): 403-406.
3	WANG L F, WANG F S, GERSHWIN M E. Human autoimmune diseases: a comprehensive update[J]. J Intern Med, 2015, 278(4): 369-395.
4	CROW M K, OLFERIEV M, KIROU K A. Type Ⅰ interferons in autoimmune disease[J]. Annu Rev Pathol, 2019, 14: 369-393.
5	SURACE A E A, HEDRICH C M. The role of epigenetics in autoimmune/inflammatory disease[J]. Front Immunol, 2019, 10: 1525.
6	LERNER A, SHOENFELD Y, MATTHIAS T. Adverse effects of gluten ingestion and advantages of gluten withdrawal in nonceliac autoimmune disease[J]. Nutr Rev, 2017, 75(12): 1046-1058.
7	RA J C, KANG S K, SHIN I S, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells[J]. J Transl Med, 2011, 9: 181.
8	MUNIR H, MCGETTRICK H M. Mesenchymal stem cell therapy for autoimmune disease: risks and rewards[J]. Stem Cells Dev, 2015, 24(18): 2091-2100.
9	RHEE K J, LEE J I, EOM Y W. Mesenchymal stem cell-mediated effects of tumor support or suppression[J]. Int J Mol Sci, 2015, 16(12): 30015-30033.
10	TSUJI W, RUBIN J P, MARRA K G. Adipose-derived stem cells: implications in tissue regeneration[J]. World J Stem Cells, 2014, 6(3): 312-321.
11	AGRAWAL I, JHA S. Comprehensive review of ASC structure and function in immune homeostasis and disease[J]. Mol Biol Rep, 2020, 47(4): 3077-3096.
12	ZUK P A, ZHU M, MIZUNO H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies[J]. Tissue Eng, 2001, 7(2): 211-228.
13	KOCAN B, MAZIARZ A, TABARKIEWICZ J, et al. Trophic activity and phenotype of adipose tissue-derived mesenchymal stem cells as a background of their regenerative potential[J]. Stem Cells Int, 2017, 2017: 1653254.
14	MARIA A T, MAUMUS M, LE QUELLEC A, et al. Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis[J]. Clin Rev Allergy Immunol, 2017, 52(2): 234-259.
15	CHO K S, ROH H J. Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases[J]. Curr Stem Cell Res Ther, 2010, 5(2): 111-115.
16	CHEN Y D, YU Q, HU Y F, et al. Current research and use of mesenchymal stem cells in the therapy of autoimmune diseases[J]. Curr Stem Cell Res Ther, 2019, 14(7): 579-582.
17	NARAYAN S, KOLLY L, SO A, et al. Increased interleukin-10 production by ASC-deficient CD4⁺ T cells impairs bystander T-cell proliferation[J]. Immunology, 2011, 134(1): 33-40.
18	HEO J S, CHOI Y, KIM H O. Adipose-derived mesenchymal stem cells promote M2 macrophage phenotype through exosomes[J]. Stem Cells Int, 2019, 2019: 7921760.
19	MA S, XIE N, LI W, et al. Immunobiology of mesenchymal stem cells[J]. Cell Death Differ, 2014, 21(2): 216-225.
20	HARRELL C R, JOVICIC N, DJONOV V, et al. Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases[J]. Cells, 2019, 8(12): E1605.
21	TOH W S, LAI R C, ZHANG B, et al. MSC exosome works through a protein-based mechanism of action[J]. Biochem Soc Trans, 2018, 46(4): 843-853.
22	FATHOLLAHI A, GABALOU N B, ASLANI S. Mesenchymal stem cell transplantation in systemic lupus erythematous, a mesenchymal stem cell disorder[J]. Lupus, 2018, 27(7): 1053-1064.
23	CHOI E W, SHIN I S, PARK S Y, et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation[J]. Arthritis Rheum, 2012, 64(1): 243-253.
24	WEI S, XIE S, YANG Z, et al. Allogeneic adipose-derived stem cells suppress mTORC1 pathway in a murine model of systemic lupus erythematosus[J]. Lupus, 2019, 28(2): 199-209.
25	MATSUDA S, KOTANI T, SAITO T, et al. Low-molecular-weight heparin enhanced therapeutic effects of human adipose-derived stem cell administration in a mouse model of lupus nephritis[J]. Front Immunol, 2021, 12: 792739.
26	RANJBAR A, HASSANZADEH H, JAHANDOUST F, et al. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: results of a phase I clinical trial[J]. Curr Res Transl Med, 2022, 70(2): 103324.
27	ZHOU B, YUAN J D, ZHOU Y X, et al. Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis[J]. Clin Immunol, 2011, 141(3): 328-337.
28	GARIMELLA M G, KOUR S, PIPRODE V, et al. Adipose-derived mesenchymal stem cells prevent systemic bone loss in collagen-induced arthritis[J]. J Immunol, 2015, 195(11): 5136-5148.
29	VIJ R, STEBBINGS K A, KIM H, et al. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase Ⅰ/Ⅱa, open-label, non-randomized pilot trial[J]. Stem Cell Res Ther, 2022, 13(1): 88.
30	LIN H P, CHAN T M, FU R H, et al. Applicability of adipose-derived stem cells in type 1 diabetes mellitus[J]. Cell Transplant, 2015, 24(3): 521-532.
31	IKEMOTO T, TOKUDA K, WADA Y M, et al. Adipose tissue from type 1 diabetes mellitus patients can be used to generate insulin-producing cells[J]. Pancreas, 2020, 49(9): 1225-1231.
32	DANG L T, BUI A N, LE-THANH NGUYEN C, et al. Intravenous infusion of human adipose tissue-derived mesenchymal stem cells to treat type 1 diabetic mellitus in mice: an evaluation of grafted cell doses[J]. Adv Exp Med Biol, 2018, 1083: 145-156.
33	HASHEMI S M, HASSAN Z M, HOSSEIN-KHANNAZER N, et al. Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice[J]. Inflammopharmacology, 2020, 28(2): 585-601.
34	DANTAS J R, ARAÚJO D B, SILVA K R, et al. Adipose tissue-derived stromal/stem cells⁺ cholecalciferol: a pilot study in recent-onset type 1 diabetes patients[J]. Arch Endocrinol Metab, 2021, 65(3): 342-351.
35	THAKKAR U G, TRIVEDI H L, VANIKAR A V, et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus[J]. Cytotherapy, 2015, 17(7): 940-947.
36	GARCÍA-OLMO D, GARCÍA-ARRANZ M, HERREROS D, et al. A phase Ⅰ clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation[J]. Dis Colon Rectum, 2005, 48(7): 1416-1423.
37	CHO Y B, LEE W Y, PARK K J, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study[J]. Cell Transplant, 2013, 22(2): 279-285.
38	DE LA PORTILLA F, ALBA F, GARCÍA-OLMO D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase Ⅰ/Ⅱa clinical trial[J]. Int J Colorectal Dis, 2013, 28(3): 313-323.
39	GARCIA-OLMO D, HERREROS D, PASCUAL I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase Ⅱ clinical trial[J]. Dis Colon Rectum, 2009, 52(1): 79-86.
40	PARK K J, RYOO S B, KIM J S, et al. Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn's disease: a pilot clinical trial[J]. Colorectal Dis, 2016, 18(5): 468-476.
41	CHOI S, RYOO S B, PARK K J, et al. Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn's disease: a phase Ⅱ clinical trial for safety and efficacy[J]. Tech Coloproctol, 2017, 21(5): 345-353.
42	WU Y, HUANG S, ENHE J, et al. Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice[J]. Int Wound J, 2014, 11(6): 701-710.
43	MOODLEY Y, ATIENZA D, MANUELPILLAI U, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury[J]. Am J Pathol, 2009, 175(1): 303-313.
44	ZHAO F, ZHANG Y F, LIU Y G, et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats[J]. Transplant Proc, 2008, 40(5): 1700-1705.
45	MARIA A T, TOUPET K, MAUMUS M, et al. Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis[J]. J Autoimmun, 2016, 70: 31-39.
46	SCUDERI N, CECCARELLI S, ONESTI M G, et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis[J]. Cell Transplant, 2013, 22(5): 779-795.
47	COLEMAN S R. Structural fat grafting: more than a permanent filler[J]. Plast Reconstr Surg, 2006, 118(3 Suppl): 108S-120S.
48	STRONG A L, ADIDHARMA W, BROWN O H, et al. Fat grafting subjectively improves facial skin elasticity and hand function of scleroderma patients[J]. Plast Reconstr Surg Glob Open, 2021, 9(1): e3373.
49	GHEISARI M, AHMADZADEH A, NOBARI N, et al. Autologous fat grafting in the treatment of facial scleroderma[J]. Dermatol Res Pract, 2018, 2018: 6568016.
50	MAGALON G, DAUMAS A, SAUTEREAU N, et al. Regenerative approach to scleroderma with fat grafting[J]. Clin Plast Surg, 2015, 42(3): 353-364, viii-ix.
51	GUILLAUME-JUGNOT P, DAUMAS A, MAGALON J, et al. State of the art. Autologous fat graft and adipose tissue-derived stromal vascular fraction injection for hand therapy in systemic sclerosis patients[J]. Curr Res Transl Med, 2016, 64(1): 35-42.
52	MENTER A, GOTTLIEB A, FELDMAN S R, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics[J]. J Am Acad Dermatol, 2008, 58(5): 826-850.
53	ARMSTRONG A W, READ C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review[J]. JAMA, 2020, 323(19): 1945-1960.
54	KIM W B, JEROME D, YEUNG J. Diagnosis and management of psoriasis[J]. Can Fam Physician, 2017, 63(4): 278-285.
55	ROKUNOHE A, MATSUZAKI Y, ROKUNOHE D, et al. Immunosuppressive effect of adipose-derived stromal cells on imiquimod-induced psoriasis in mice[J]. J Dermatol Sci, 2016, 82(1): 50-53.
56	DE JESUS M M, SANTIAGO J S, TRINIDAD C V, et al. Autologous adipose-derived mesenchymal stromal cells for the treatment of psoriasis vulgaris and psoriatic arthritis: a case report[J]. Cell Transplant, 2016, 25(11): 2063-2069.
57	COMELLA K, PARLO M, DALY R, et al. First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study[J]. Int Med Case Rep J, 2018, 11: 59-64.
58	YAO D N, YE S Y, HE Z Y, et al. Adipose-derived mesenchymal stem cells (AD-MSCs) in the treatment for psoriasis: results of a single-arm pilot trial[J]. Ann Transl Med, 2021, 9(22): 1653.

NCT Number	Title	Status	Condition	Intervention
NCT05308836	Evaluating Safety of Adipose-Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment	Recruiting	T1DM	AD-MSCs were given intravenously
NCT03840343	Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Recruiting	T2DM T1DM Diabetic nephropathy	Autologous AD-MCSs were injected twice at 0 and 3 months at different doses. Intraarterial injection of one kidney
NCT04869761	Stem Cell Therapy for Chronic Kidney Disease	Recruiting	Chronic kidney disease T2DM T1DM Diabetic nephropathy	Allogeneic Ad-MSCs were given once or twice
NCT03609905	Adipose Mesenchymal Stem Cells （AMSC） for Treatment of Ulcerative Colitis	Recruiting	UC	Under colonoscopy， 5×10⁷/100 mL AD-MSCs were injected into different parts of the colonic submucosa. Once a week， twice in total
NCT04312113	Angiographic Delivery of AD-MSC for Ulcerative Colitis	Recruiting	UC	AD-MSCs were delivered to the inferior mesenteric artery by interventional radiology
NCT04785027	Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined with AD-MSCs in Psoriasis	Recruiting	Psoriasis	Allogeneic AD-MSCs were intravenously injected 2×10⁶/kg for 5 times
NCT04275024	Efficacy and Safety of AD-MSCs plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 2×10⁷/kg for 12 weeks
NCT03392311	Efficacy and Safety of AD-MSCs plus Calpocitriol Ointment in Patients with Moderate to Severe Psoriasis	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 2×10⁷/kg for 12 weeks
NCT03265613	Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients with Moderate to Severe Psoriasis	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 5×10⁶/kg for 12 weeks

NCT Number	Title	Status	Condition	Intervention
NCT05308836	Evaluating Safety of Adipose-Derived Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Treatment	Recruiting	T1DM	AD-MSCs were given intravenously
NCT03840343	Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Recruiting	T2DM T1DM Diabetic nephropathy	Autologous AD-MCSs were injected twice at 0 and 3 months at different doses. Intraarterial injection of one kidney
NCT04869761	Stem Cell Therapy for Chronic Kidney Disease	Recruiting	Chronic kidney disease T2DM T1DM Diabetic nephropathy	Allogeneic Ad-MSCs were given once or twice
NCT03609905	Adipose Mesenchymal Stem Cells （AMSC） for Treatment of Ulcerative Colitis	Recruiting	UC	Under colonoscopy， 5×10⁷/100 mL AD-MSCs were injected into different parts of the colonic submucosa. Once a week， twice in total
NCT04312113	Angiographic Delivery of AD-MSC for Ulcerative Colitis	Recruiting	UC	AD-MSCs were delivered to the inferior mesenteric artery by interventional radiology
NCT04785027	Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined with AD-MSCs in Psoriasis	Recruiting	Psoriasis	Allogeneic AD-MSCs were intravenously injected 2×10⁶/kg for 5 times
NCT04275024	Efficacy and Safety of AD-MSCs plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 2×10⁷/kg for 12 weeks
NCT03392311	Efficacy and Safety of AD-MSCs plus Calpocitriol Ointment in Patients with Moderate to Severe Psoriasis	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 2×10⁷/kg for 12 weeks
NCT03265613	Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients with Moderate to Severe Psoriasis	Recruiting	Psoriasis	AD-MSCs were intravenously injected at a dose of 5×10⁶/kg for 12 weeks

[1]	GU Nan-nan, LI Chun-bo. Research progresses in transcutaneous vagus nerve stimulation [J]. , 2020, 40(4): 539-.
[2]	CHEN Xu-zhuo1, MAO Yi1, ZHENG Ji-si1, JIANG Wen-bo2, ZHANG Shan-yong1, CHEN Ke3, YANG Chi1. Clinical application of Chinese customized TC4/UHMWPE connected total temporomandibular joint prostheses [J]. , 2019, 39(9): 1052-.
[3]	ZHENG Ji-si， ZHANG Shan-yong， YANG Chi， YU Yang， JIANG Wen-bo， LI Hui-wu， WANG Xiang-yu， JIAO Zi-Xian，ZHONG Xiao-Qi . Clinical application of domestic customized 3D-printing total temporomandibular joint prostheses [J]. , 2016, 36(9): 1287-.
[4]	XUE Xiao-mei， CAO Hui-min， YOU Sha-sha， HE Bin. Application of nano drug delivery system to treatment of myocardial ischemia [J]. , 2016, 36(9): 1356-.
[5]	CHEN Hui, LIU Hong-hu. Advances of clinical application of micro-implant anchorage to orthodontics [J]. , 2014, 34(11): 1700-.
[6]	FENG Xiao-xiao, ZHOU Li-jia, WU Jian-yong. Clinical application of remote ischemic conditioning [J]. , 2013, 33(3): 363-.
[7]	LIU Hua, LING Wei, CAO Hui. Effects of immune-enhanced enteral nutrition and parenteral nutrition on immune \|and nutritional function in elderly patients with gastric cancer after total gastrectomy [J]. , 2011, 31(7): 1000-.
[8]	MA Dong-hong. Techniques of immunoassays for serum thyroid-stimulating hormone [J]. , 2010, 30(3): 356-.
[9]	GAO Yan-hong. Epigenetic regulation and human common diseases [J]. , 2009, 29(10): 1256-.